IDRA - Idera Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.17
-0.38 (-14.90%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.55
Open2.40
Bid0.00 x 0
Ask4.70 x 8100
Day's Range1.84 - 2.40
52 Week Range1.30 - 2.87
Volume14,025,470
Avg. Volume2,794,088
Market Cap422.868M
Beta1.99
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today
    Motley Fool12 hours ago

    Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today

    Find out which company announced a merger.

  • BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love
    Motley Fool12 hours ago

    BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love

    Is this a merger out of weakness and necessity? Wall Street might think so.

  • American City Business Journals14 hours ago

    Durham's BioCryst merging with Idera, moving some ops out of state

    Durham’s BioCryst Pharmaceuticals (BCRX) will merge with Exton, Pennsylvania-based Idera Pharmaceuticals (IDRA) in an all-stock deal, the companies said Monday. Idera’s CEO Vincent Milano will lead the combined company, with BioCryst’s CEO Jon Stonehouse serving as a member of its board of directors. Milano will also serve as a member of the combined company’s board, which will be chaired by Robert Ingram, pharmaceutical executive and former CEO and Chairman of Glaxo/Wellcome.

  • MarketWatch20 hours ago

    BioCryst and Idera to merge into rare disease company

    BioCryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. announced early Monday plans to merge into a rare disease company. Shares of both companies were halted in premarket trade. Under the deal, ...

  • 7 High-Risk, High-Reward Stocks to Buy Now
    InvestorPlace12 days ago

    7 High-Risk, High-Reward Stocks to Buy Now

    The company will next report results on Feb. 9, before the bell. Analysts are looking for earnings of 44-cents-per-share on revenues of $4 billion. When the company last reported on Nov. 10, a loss of 33-cents-per-share beat estimates by 10 cents on a 1.8% decline in revenues.

  • Where Idera Pharmaceuticals Inc (NASDAQ:IDRA) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.20 days ago

    Where Idera Pharmaceuticals Inc (NASDAQ:IDRA) Stands In Terms Of Earnings Growth Against Its Industry

    Examining Idera Pharmaceuticals Inc’s (NASDAQ:IDRA) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...

  • Capital Cube28 days ago

    Idera Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IDRA) : December 26, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Idera Pharmaceuticals, Inc. a score of 32. Our analysis is based on comparing Idera Pharmaceuticals, Inc. with the following peers – Dynavax Technologies Corporation, Ionis Pharmaceuticals, Inc., Amgen Inc., Agenus Inc., Celldex Therapeutics, Inc., Ligand Pharmaceuticals Incorporated, Celgene Corporation, Abbott Laboratories, Merck & Co., Inc. and Johnson ... Read more (Read more...)

  • Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : December 22, 2017
    Capital Cubelast month

    Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : December 22, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Idera Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Idera Pharmaceuticals, Inc. : December 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 3 Top Stocks Under $5
    Motley Fool2 months ago

    3 Top Stocks Under $5

    Investors may want to put Idera Pharmaceuticals, Yamana Gold, and Ekso Bionics on their watchlists.

  • Capital Cube2 months ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : November 21, 2017
    Capital Cube2 months ago

    Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : November 21, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Idera Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : November 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is the Options Market Predicting a Spike in Idera (IDRA) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Idera (IDRA) Stock?

    Investors in Idera (IDRA) need to pay close attention to the stock based on moves in the options market lately.

  • Why Idera Pharmaceuticals Inc. Jumped Higher Today
    Motley Fool2 months ago

    Why Idera Pharmaceuticals Inc. Jumped Higher Today

    New phase 1/2 trial data show the biotech's drug candidate IMO-2125 is working.

  • Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cube2 months ago

    Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Idera Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Idera Pharmaceuticals, Inc. – Dynavax Technologies Corporation, Ionis Pharmaceuticals, Inc., Amgen Inc., Agenus Inc., Abbott Laboratories, Merck & Co., Inc., Biogen Inc. and Pfizer Inc. (DVAX-US, IONS-US, AMGN-US, ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : November 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Press3 months ago

    Idera reports 3Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 10 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today
    Motley Fool3 months ago

    Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today

    It makes sense on paper, but is little more than wishful thinking in reality.

  • Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today
    Motley Fool3 months ago

    Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today

    The biopharma announced a massive public stock offering.

  • Capital Cube3 months ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : October 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : October 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 3 Small-Cap Biotech Stocks to Buy This Fall
    Motley Fool4 months ago

    3 Small-Cap Biotech Stocks to Buy This Fall

    Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners.

  • Is It Time To Buy Idera Pharmaceuticals Inc (IDRA)?
    Simply Wall St.4 months ago

    Is It Time To Buy Idera Pharmaceuticals Inc (IDRA)?

    Idera Pharmaceuticals Inc (NASDAQ:IDRA), a pharmaceuticals, biotechnology and life sciences company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple ofRead More...

  • Capital Cube4 months ago

    ETFs with exposure to Idera Pharmaceuticals, Inc. : September 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Idera Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IDRA-US. Comparing the performance and risk of Idera Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)